Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
130 results about "Melanocortin receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Melanocortin receptors are members of the rhodopsin family of 7-transmembrane G protein-coupled receptors.
Methods of activating a melanocortin-4 receptor pathway in obese subjects
ActiveUS8476227B2Induce weight lossOrganic active ingredientsPeptide/protein ingredientsDefined ProcedureMC4 Receptor
Methods and therapeutics are provided for treating metabolic disorders by activation of melanocortin signaling pathways. Generally, the methods and therapeutics can induce activation of melanocortin receptor signaling to increase energy expenditure and induce weight loss. In one embodiment, a method for performing a diagnostic procedure can be chosen, energy expenditure then assess in light of the diagnostic procedure and a definitive procedure(s) can be selected dependent on the outcome of the energy assessment. In another embodiment, a diagnostic procedure can be chosen to activate melanocortin receptor pathways, energy expenditure can be assessed and a definitive procedure(s) can be chosen that selectively and optimally activate melanocortin receptor pathways.
Owner:ETHICON ENDO SURGERY INC +1
Metallopeptide compositions for treatment of sexual dysfunction
Owner:PALATIN TECH INC
Substituted melanocortin receptor-specific piperazine compounds
Melanocortin receptor-specific compounds of the general formulas and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, L is a linker, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q includes a substituted or unsubstituted aromatic carbocyclic ring, R6, R7, y and z are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration, and optionally with one or two additional ring substituents as defined, which compounds bind to one or more melanocortin receptors and are optionally an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.
Owner:PALATIN TECH INC
Aminopiperidine derivatives, preparation thereof and therapeutic use thereof
The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment and in the prevention of obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.
Owner:SANOFI AVENTIS SA
Substituted piperazinyl amides and methods of use
Selected substituted piperazine compounds of Formula I are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
Owner:AMGEN INC
Novel Peptides for Use in the Treatment of Obesity
The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
Owner:NOVO NORDISK AS
Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
InactiveUS20090305960A1Lower Level RequirementsMetabolism disorderImmunoglobulinsCyclic peptideMelanocortin receptor
Melanocortin receptor-specific cyclic peptides of the formulawhere R1, R2, R3, R4, x and y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes, including obesity, diabetes, modulation of feeding behavior and related metabolic syndrome.
Owner:PALATIN TECH INC
Substituted piperidines and methods of use
Selected substituted piperidine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
Owner:AMGEN INC
Melanocortin Receptor-Specific Peptides for Treatment of Sexual Dysfunction
ActiveUS20110065652A1Good blood pressureImmunoglobulinsCyclic peptide ingredientsDiseaseCyclic peptide
A melanocortin receptor agonist cyclic peptide of the formulawhere R, x and y are as defined in the specification, compositions and formulations including the peptide of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes, including sexual dysfunction such as male erectile dysfunction and female sexual dysfunction.
Owner:PALATIN TECH INC
Melanocortin receptor-specific compounds
A melanocortin receptor-specific compound of the general formula of structure I:where X, R1, R2a, R2b, R3, R4a, R4b, R5a and R5b are as defined in the specification, which compound binds with high affinity to one or more melanocortin receptors and is optionally an agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.
Owner:PALATIN TECH INC
Linear and cyclic melanocortin receptor-specific peptidomimetics
ActiveUS8114844B2Oxytocins/vasopressinsCyclic peptide ingredientsMelanocortin 1 receptorMelanocortin receptor
Linear and cyclic peptidomimetics which bind to one or more melanocortin receptors are provided, which peptidomimetics include at least one ring-constrained amino acid surrogate of formula I:where R1, R2, R3, R4, R5, R6, R7, R8, and y are as defined in the specification, together with methods for synthesizing ring-constrained amino acid surrogates of formula I and peptidomimetics incorporating the same, and methods of use of peptidomimetics in the treatment of various diseases, syndromes and conditions.
Owner:PALATIN TECH INC
Cyclic peptides for treatment of cachexia
A highly selective melanocortin-4 receptor antagonist cyclic hexapeptide of the formula where R1, R2, R3a, R3b, R4, R5, x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.
Owner:PALATIN TECH INC
Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics
Linear and cyclic peptidomimetics which bind to one or more melanocortin receptors are provided, which peptidomimetics include at least one ring-constrained amino acid surrogate of formula I:where R1, R2, R3, R4, R5, R6, R7, R8, and y are as defined in the specification, together with methods for synthesizing ring-constrained amino acid surrogates of formula I and peptidomimetics incorporating the same, and methods of use of peptidomimetics in the treatment of various diseases, syndromes and conditions.
Owner:PALATIN TECH INC
Melanocortin receptor-specific piperazine compounds with diamine groups
Melanocortin receptor-specific compounds with diamine groups of the general formulaand pharmaceutically acceptable salts thereof, where W is a diamine heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, J, Q, L1, L2, L3, R1a, R1b, R2a, R2b and X are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.
Owner:PALATIN TECH INC
Cyclic peptides for treatment for cachexia
A highly selective melanocortin-4 receptor antagonist cyclic peptide of the formulawhere R1, R2, R3, R4a, R4b, R5, R6, R7, x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.
Owner:PALATIN TECH INC
Melanocortin metallopeptide constructs, combinatorial libraries and applications
InactiveUS7049398B1Rapid and efficient complexationTripeptide ingredientsRadioactive preparation carriersCombinatorial chemistryMelanocortin receptor
Metallopeptides and metallopeptide combinatorial libraries specific for melanocortin receptors are provided, for use in biological, pharmaceutical and related applications. The metallopeptides and combinatorial libraries are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion.
Owner:PALATIN TECH INC
Method of Inducing Melanogenesis in Humans With Mc1R Variant Alleles
A method for inducing melanogenesis in a human subject having a melanocortin 1 receptor (MC1R) variant allele associated with loss of or diminished receptor function comprises administering to said subject an amount of an α-melanocyte stimulating hormone (α-MSH) analogue effective to induce melanogenesis by the melanocytes in the skin or other epidermal tissue of the subject.
Owner:CLINUVEL PHARMA
Stable topical compositions for 1,2,4-thiadiazole derivatives
The present application provides a stable topical composition comprising a compound of 1,2,4-thiadiazole derivatives and the related thiourea derivatives. The stable topical composition may be present in various forms, including aqueous gel, cream, and emulsion. The stable topical composition may be stored at refrigerated or ambient condition for a reasonable shelf-life. The present application also provides a method of treating dermatologic disorders mediated by a melanocortin receptor using the stable topical composition. The stable composition may be delivered using a single chamber or dual chamber device. A method of preparing and delivering the stable composition is also provided.
Owner:JANSSEN PHARMA INC
Substituted piperazines and methods of use
Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
Owner:AMGEN INC
Melanocortin Receptor-Specific Compounds
A melanocortin receptor-specific compound of the general formula of structure I:where X, R1, R2a, R2b, R3, R4a, R4b, R5a and R5b are as defined in the specification, which compound binds with high affinity to one or more melanocortin receptors and is optionally an agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.
Owner:PALATIN TECH INC
Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds
ActiveUS20060287330A1Impairment of energy homeostasisOrganic active ingredientsOrganic chemistryAcyl groupHeteroatom
Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q is a substituted or unsubstituted aromatic carbocyclic ring group, L, R2a, R2b, R3a, R3b, r, x and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.
Owner:PALATIN TECH INC
SNP (single nucleotide polymorphism) marker and method for identifying MC1R (melanocortin receptor 1) genes of pig breeds and colors of pig breeds as well as application
PendingCN105648071AThe screening method is accurateEasy to operateMicrobiological testing/measurementDNA/RNA fragmentationUnknown SourceScreening method
The invention discloses an SNP (single nucleotide polymorphism) marker for identifying MC1R (melanocortin receptor 1) genes of pig breeds and colors of the pig breeds and further discloses an SNP marker primer for identifying the MC1R genes of the pig breeds and the colors of the pig breeds as well as an SNP marker method for identifying the MC1R genes of the pig breeds and the colors of the pig breeds. The molecular genetic marker is not limited by ages, sexes and the like of pigs, can be applied to early breeding of pure breeds of local black hogs and can further be used for performing pig breed and color identification and genetic relationship deduction on pork samples from unknown sources. A screening method is accurate, operation is simple, the cost is low, and the efficiency is high.
Owner:KUNMING UNIV +1
Cyclic peptides for treatment of cachexia
A highly selective melanocortin-4 receptor antagonist cyclic peptide of the formula where R1, R2, R3, R4a, R4b, R5, R6, R7, x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.
Owner:PALATIN TECH INC
Acth antagonist peptides
ActiveUS20120309696A1Reduce productionAnimal cellsPeptide/protein ingredientsAdrenal glandMelanocortin receptor
The present invention provides methods of treating overproduction of cortisol in a subject by administering to the subject a peptide that antagonizes adrenocorticotropin hormone (ACTH) to block the activation of melanocortin 2 receptors.
Owner:COLORADO SEMINARY
Linear and cyclic melanocortin receptor-specific peptides
ActiveUS7417027B2Cell receptors/surface-antigens/surface-determinantsMetabolism disorderCyclic peptideMelanocortin receptor
Linear and cyclic peptides are provided specific to one or melanocortin receptors, and which exhibit agonist, antagonist, or mixed agonist-antagonist activity. In one embodiment, a linear peptide of the following general formula is provided:
Owner:PALATIN TECH INC
Melanocortin receptor-specific piperazine compounds with diamine groups
InactiveUS20060287331A1Impairment of energy homeostasisOrganic active ingredientsOrganic chemistryHeteroatomMelanocortin receptor
Melanocortin receptor-specific compounds with diamine groups of the general formula and pharmaceutically acceptable salts thereof, where W is a diamine heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, J, Q, L1, L2, L3, R1a, R1b, R2a, R2b and X are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.
Owner:PALATIN TECH INC
Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
Disclosed is a compound of Formula I or a salt thereof, in which X, X1, X2, R1, R2, and R3 are described herein. Also disclosed are pharmaceutical compositions and methods of using the compounds of Formula I to treat disorders mediated by melanocortin-4 receptors.
Owner:UNIV DE MONTREAL
Ligands of melanocortin receptors
InactiveUS20090232838A1Improve stabilityHigh selectivityAntibacterial agentsNervous disorderChemical compoundPharmaceutical medicine
The present invention is directed to a compound according to formula, (R2R3)-B1-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-A11-A12-A13-B2-B3-R1, that act as ligands for one or more of the melanocortin receptors, the pharmaceutically-acceptable salts thereof, to methods of using such peptides to treat mammals and to pharmaceutical compositions useful therefore comprising said peptides.
Owner:IPSEN PHARMA SAS
Ligands of melanocortin receptors
InactiveUS8349797B2Weight increaseReduce food consumptionAntibacterial agentsNervous disorderMelanocortin 1 receptorMelanocortin receptor
The present invention is directed to a compound according to formula,(R2R3)-B1-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-A11-A12-A13-B2-B3-R1, that act as ligands for one or more of the melanocortin receptors, the pharmaceutically-acceptable salts thereof, to methods of using such peptides to treat mammals and to pharmaceutical compositions useful therefore comprising said peptides.
Owner:IPSEN PHARMA SAS
Novel Peptides for Use in the Treatment of Obesity
The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
Owner:NOVO NORDISK AS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com